Publication:
Isotretinoin treatment for folliculitis decalvans: a retrospective case-series study

dc.contributor.authorAksoy, Berna
dc.contributor.authorHapa, Aslı Altaykan
dc.contributor.authorMutlu, Emine
dc.contributor.institutionAksoy, Berna, Department of Dermatology, Bahçeşehir Üniversitesi, Istanbul, Turkey
dc.contributor.institutionHapa, Aslı Altaykan, Dermatology Clinic, Buca Seyfi Demirsoy Training and Research Hospital, Izmir, Turkey
dc.contributor.institutionMutlu, Emine, Department of Dermatology, Celal Bayar Üniversitesi Tip Fakültesi, Manisa, Turkey
dc.date.accessioned2025-10-05T16:11:11Z
dc.date.issued2018
dc.description.abstractBackground: The literature includes only a few reports of oral isotretinoin for the treatment of folliculitis decalvans (FD). This study aimed to determine the most effective dose and duration of oral isotretinoin monotherapy for achieving remission in FD patients. Methods: This retrospective case series study included FD patients that were treated with oral isotretinoin. Patient demographics, clinical characteristics, and treatment details were obtained from the patients’ medical records. Patients were contacted via telephone after treatment was completed and asked about any relapses, time period of relapses, and the long-term effects of the treatment. Results: The study included 39 male patients with a mean age of 37.9 ± 15.5 years. All of the patients received oral isotretinoin 0.1–1.02 mg/kg/day (10–90 mg/day) for a median duration of 2.5 months (range: 1–8 months). In all, 82.0% of patients healed after the treatment. Patients that received oral isotretinoin ≥0.4 mg/kg/day for ≥3 months responded better, and 66% of them never relapsed. Conclusion: Contrary to general belief, oral isotretinoin monotherapy resulted in complete response in the majority of patients in this study. Based on this finding, we think oral isotretinoin ≥0.4 mg/kg/day should be given for ≥3 months to minimize the likelihood of relapse. In addition, we think oral isotretinoin monotherapy should be considered a promising treatment alternative for FD that warrants further research. © 2021 Elsevier B.V., All rights reserved.
dc.identifier.doi10.1111/ijd.13874
dc.identifier.endpage253
dc.identifier.issn13654632
dc.identifier.issn00119059
dc.identifier.issue2
dc.identifier.pubmed29313960
dc.identifier.scopus2-s2.0-85040742328
dc.identifier.startpage250
dc.identifier.urihttps://doi.org/10.1111/ijd.13874
dc.identifier.urihttps://hdl.handle.net/20.500.14719/11747
dc.identifier.volume57
dc.language.isoen
dc.publisherBlackwell Publishing Ltd
dc.relation.sourceInternational Journal of Dermatology
dc.subject.authorkeywordsIsotretinoin
dc.subject.authorkeywordsDermatologic Agents
dc.subject.authorkeywordsIsotretinoin
dc.subject.authorkeywordsIsotretinoin
dc.subject.authorkeywordsDermatological Agent
dc.subject.authorkeywordsAdult
dc.subject.authorkeywordsAged
dc.subject.authorkeywordsAlopecia
dc.subject.authorkeywordsArticle
dc.subject.authorkeywordsCase Study
dc.subject.authorkeywordsClinical Article
dc.subject.authorkeywordsControlled Study
dc.subject.authorkeywordsDrug Efficacy
dc.subject.authorkeywordsDrug Safety
dc.subject.authorkeywordsElectronic Medical Record
dc.subject.authorkeywordsFolliculitis
dc.subject.authorkeywordsFolliculitis Decalvans
dc.subject.authorkeywordsHuman
dc.subject.authorkeywordsHyperlipidemia
dc.subject.authorkeywordsInformed Consent
dc.subject.authorkeywordsMale
dc.subject.authorkeywordsRelapse
dc.subject.authorkeywordsRetrospective Study
dc.subject.authorkeywordsTreatment Duration
dc.subject.authorkeywordsTreatment Response
dc.subject.authorkeywordsXerosis
dc.subject.authorkeywordsAdolescent
dc.subject.authorkeywordsComplication
dc.subject.authorkeywordsMiddle Aged
dc.subject.authorkeywordsRecurrent Disease
dc.subject.authorkeywordsRemission
dc.subject.authorkeywordsVery Elderly
dc.subject.authorkeywordsYoung Adult
dc.subject.authorkeywordsAdolescent
dc.subject.authorkeywordsAdult
dc.subject.authorkeywordsAged
dc.subject.authorkeywordsAged, 80 And Over
dc.subject.authorkeywordsAlopecia
dc.subject.authorkeywordsDermatologic Agents
dc.subject.authorkeywordsFolliculitis
dc.subject.authorkeywordsHumans
dc.subject.authorkeywordsIsotretinoin
dc.subject.authorkeywordsMale
dc.subject.authorkeywordsMiddle Aged
dc.subject.authorkeywordsRecurrence
dc.subject.authorkeywordsRemission Induction
dc.subject.authorkeywordsRetrospective Studies
dc.subject.authorkeywordsYoung Adult
dc.subject.indexkeywordsisotretinoin
dc.subject.indexkeywordsdermatological agent
dc.subject.indexkeywordsadult
dc.subject.indexkeywordsaged
dc.subject.indexkeywordsalopecia
dc.subject.indexkeywordsArticle
dc.subject.indexkeywordscase study
dc.subject.indexkeywordsclinical article
dc.subject.indexkeywordscontrolled study
dc.subject.indexkeywordsdrug efficacy
dc.subject.indexkeywordsdrug safety
dc.subject.indexkeywordselectronic medical record
dc.subject.indexkeywordsfolliculitis
dc.subject.indexkeywordsfolliculitis decalvans
dc.subject.indexkeywordshuman
dc.subject.indexkeywordshyperlipidemia
dc.subject.indexkeywordsinformed consent
dc.subject.indexkeywordsmale
dc.subject.indexkeywordsrelapse
dc.subject.indexkeywordsretrospective study
dc.subject.indexkeywordstreatment duration
dc.subject.indexkeywordstreatment response
dc.subject.indexkeywordsxerosis
dc.subject.indexkeywordsadolescent
dc.subject.indexkeywordscomplication
dc.subject.indexkeywordsmiddle aged
dc.subject.indexkeywordsrecurrent disease
dc.subject.indexkeywordsremission
dc.subject.indexkeywordsvery elderly
dc.subject.indexkeywordsyoung adult
dc.subject.indexkeywordsAdolescent
dc.subject.indexkeywordsAdult
dc.subject.indexkeywordsAged
dc.subject.indexkeywordsAged, 80 and over
dc.subject.indexkeywordsAlopecia
dc.subject.indexkeywordsDermatologic Agents
dc.subject.indexkeywordsFolliculitis
dc.subject.indexkeywordsHumans
dc.subject.indexkeywordsIsotretinoin
dc.subject.indexkeywordsMale
dc.subject.indexkeywordsMiddle Aged
dc.subject.indexkeywordsRecurrence
dc.subject.indexkeywordsRemission Induction
dc.subject.indexkeywordsRetrospective Studies
dc.subject.indexkeywordsYoung Adult
dc.titleIsotretinoin treatment for folliculitis decalvans: a retrospective case-series study
dc.typeArticle
dcterms.referencesOtberg, Nina, Folliculitis decalvans, Dermatologic Therapy, 21, 4, pp. 238-244, (2008), Bunagan, Marry Jo Kristine, Retrospective review of folliculitis decalvans in 23 patients with course and treatment analysis of long-standing cases, Journal of Cutaneous Medicine and Surgery, 19, 1, pp. 45-49, (2015), Tietze, Julia Katharina, Oral isotretinoin as the most effective treatment in folliculitis decalvans: A retrospective comparison of different treatment regimens in 28 patients, Journal of the European Academy of Dermatology and Venereology, 29, 9, pp. 1816-1821, (2015), Douwes, Kathrin Elisabeth, Simultaneous occurrence of folliculitis decalvans capillitii in identical twins, British Journal of Dermatology, 143, 1, pp. 195-197, (2000), Gemmeke, Astrid, Folliculitis decalvans of the scalp: Response to triple therapy with isotreunoin, clindamycin, and prednisolone, Acta Dermatovenerologica Alpina, Pannonica et Adriatica, 15, 4, pp. 184-186, (2006), Vañõ-Galván, Sergio, Folliculitis decalvans: A multicentre review of 82 patients, Journal of the European Academy of Dermatology and Venereology, 29, 9, pp. 1750-1757, (2015)
dspace.entity.typePublication
local.indexed.atScopus
person.identifier.scopus-author-id24342773300
person.identifier.scopus-author-id27267753900
person.identifier.scopus-author-id57200308691

Files